tradingkey.logo

Dexcom Inc

DXCM
69.970USD
+0.080+0.11%
Close 02/06, 16:00ETQuotes delayed by 15 min
27.29BMarket Cap
37.99P/E TTM

Dexcom Inc

69.970
+0.080+0.11%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Dexcom Inc

Currency: USD Updated: 2026-02-06

Key Insights

Dexcom Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 86.02.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dexcom Inc's Score

Industry at a Glance

Industry Ranking
39 / 205
Overall Ranking
127 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Dexcom Inc Highlights

StrengthsRisks
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.03B.
Undervalued
The company’s latest PE is 37.99, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 388.08M shares, increasing 0.05% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 103.84K shares of this stock.

Analyst Rating

Based on 31 analysts
Buy
Current Rating
86.015
Target Price
+23.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Dexcom Inc is 9.28, ranking 12 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.21B, representing a year-over-year increase of 21.64%, while its net profit experienced a year-over-year increase of 110.85%.

Score

Industry at a Glance

Previous score
9.28
Change
0

Financials

9.02

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

9.60

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.78

Dexcom Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Dexcom Inc is 3.97, ranking 198 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 37.99, which is 358.72% below the recent high of 174.26 and 21.62% above the recent low of 29.77.

Score

Industry at a Glance

Previous score
3.97
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 39/205
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Dexcom Inc is 8.45, ranking 31 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 84.20, with a high of 112.00 and a low of 68.00.

Score

Industry at a Glance

Previous score
8.45
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 31 analysts
Buy
Current Rating
86.015
Target Price
+23.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

114
Total
6
Median
9
Average
Company name
Ratings
Analysts
Dexcom Inc
DXCM
31
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Medtronic PLC
MDT
31
Zimmer Biomet Holdings Inc
ZBH
30
Insulet Corp
PODD
28
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Dexcom Inc is 6.93, ranking 75 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 75.43 and the support level at 65.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.94
Change
-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.045
Neutral
RSI(14)
47.523
Neutral
STOCH(KDJ)(9,3,3)
15.841
Oversold
ATR(14)
2.358
Low Volatility
CCI(14)
-148.877
Sell
Williams %R
80.767
Oversold
TRIX(12,20)
0.271
Sell
StochRSI(14)
3.109
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
70.968
Sell
MA10
72.225
Sell
MA20
71.449
Sell
MA50
68.365
Buy
MA100
66.798
Buy
MA200
74.238
Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Dexcom Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 103.93%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 48.89M shares, representing 12.54% of shares outstanding, with 3.95% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
49.27M
+2.34%
BlackRock Institutional Trust Company, N.A.
24.32M
+0.32%
State Street Investment Management (US)
16.86M
-0.02%
Baillie Gifford & Co.
Star Investors
15.88M
-4.93%
Geode Capital Management, L.L.C.
10.96M
+1.83%
Invesco Capital Management (QQQ Trust)
8.75M
+6.46%
Citadel Advisors LLC
6.78M
+395.24%
Nuveen LLC
6.15M
-15.70%
Jennison Associates LLC
10.09M
-12.39%
Norges Bank Investment Management (NBIM)
5.19M
+4.79%
1
2

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dexcom Inc is 6.55, ranking 57 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
6.55
Change
0
Beta vs S&P 500 index
1.49
VaR
+4.15%
240-Day Maximum Drawdown
+39.57%
240-Day Volatility
+43.00%

Return

Best Daily Return
60 days
+6.00%
120 days
+6.22%
5 years
+19.38%
Worst Daily Return
60 days
-5.21%
120 days
-14.63%
5 years
-40.66%
Sharpe Ratio
60 days
+2.69
120 days
-0.47
5 years
+0.07

Risk Assessment

Maximum Drawdown
240 days
+39.57%
3 years
+60.95%
5 years
+66.32%
Return-to-Drawdown Ratio
240 days
-0.58
3 years
-0.21
5 years
-0.10
Skewness
240 days
-0.06
3 years
-3.65
5 years
-1.82

Volatility

Realised Volatility
240 days
+43.00%
5 years
+48.31%
Standardised True Range
240 days
+3.64%
5 years
+5.15%
Downside Risk-Adjusted Return
120 days
-47.02%
240 days
-47.02%
Maximum Daily Upside Volatility
60 days
+26.30%
Maximum Daily Downside Volatility
60 days
+17.97%

Liquidity

Average Turnover Rate
60 days
+0.94%
120 days
+1.01%
5 years
--
Turnover Deviation
20 days
+3.34%
60 days
-6.86%
120 days
-0.23%

Peer Comparison

Healthcare Equipment & Supplies
Dexcom Inc
Dexcom Inc
DXCM
7.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
Align Technology Inc
ALGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI